As­traZeneca CEO says Eu­rope is 'falling be­hind' on R&D and man­u­fac­tur­ing in­vest­ments

Last month
People
Pharma

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

Last month
Pharma
FDA+

Top phar­ma com­pa­nies in­creased lob­by­ing spend in first quar­ter of 2025

Last month
Pharma
FDA+

Ve­r­axa makes a SPAC deal; Il­lu­mi­na dis­clos­es lay­offs

Last month
News Briefing

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Last month
Deals
China

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Last month
People
Pharma

FDA asks No­vavax for post-mar­ket­ing da­ta of its Covid vac­cine, de­lay­ing ap­proval

Last month
Pharma
FDA+

Te­lenu­tri­tion start­up Nour­ish rais­es $70M

Last month
Health Tech

Genen­tech vet launch­es ADC start­up with $20M

Last month
Financing
Startups

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

Last month
R&D

Ake­so re­ports an­oth­er Phase 3 win for PD-1xVEGF ap­proach in lung can­cer

Last month
R&D

Reper­toire inks au­toim­mune deal with Genen­tech as it eyes a re­turn to the clin­ic

Last month
Startups
Deals

Ex­clu­sive: Chica­go start­up Grove Bio­phar­ma nabs $30M Se­ries A

Last month
Financing
Startups

Eli Lil­ly sues four tele­health com­pa­nies sell­ing com­pound­ed tirzepatide

Last month
Pharma
Law

Boehringer taps Dutch biotech for ALT pos­i­tive can­cer pact ex­ceed­ing $573M in biobucks

Last month
Deals
R&D

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

Last month
R&D
Pharma

Vac­cine biotechs say they’ve been told to stop next-gen Covid work un­der a Biden-era project

Last month
Pharma
Coronavirus

As­traZeneca re­joins PhRMA, two years af­ter leav­ing lob­by group

Last month
Pharma

Re­cent FDA staff cuts to de­lay drug hear­ing de­ci­sion by months, agency tells Van­da

Last month
FDA+
Law

Re­gen­eron to boost its US man­u­fac­tur­ing through a $3B Fu­ji­film deal

Last month
Pharma
Manufacturing

Gala­pa­gos CEO Paul Stof­fels to step down, for­mer Neumo­ra chief to lead spin­out

Last month
People

In­sur­ers have a Medicare Ad­van­tage prob­lem

Last month
Health Tech

Dana­her ex­pects about $350M in tar­iff costs; Alu­mis, Ace­lyrin ad­just deal terms

Last month
News Briefing

Ex­clu­sive: George Church start­up will study long-lived an­i­mals, hu­mans to find life-ex­tend­ing genes

Last month
Financing
Startups
First page Previous page 11121314151617 Next page Last page
A service from the Financial Times